HIGHLIGHTS
- who: Jun Xie from the University of Kentucky, United States have published the research: Cost-effectiveness of adding empagliflozin to the standard therapy for Heart Failure with Preserved Ejection Fraction from the perspective of healthcare systems in China, in the Journal: (JOURNAL)
- what: To fill the gap, the authors are the first to evaluate the cost-effectiveness of the add-on empagliflozin treatment for HFpEF, the study aims to help clinicians and decision-makers judge the economic value of this new therapy.
SUMMARY
Reduction, including higher circulating ketone levels, natriuresis, anti . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.